US-based biotech Intercept Pharmaceuticals yesterday announced its third quarter results. Investors were satisfied, indeed Intercept’s shares rose by 10% over few hours. Intercept’s main asset is undoubtedly Ocaliva (obeticholic acid), approved for the treatment of primary biliary cholangitis
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,